May. 15 at 2:50 PM
$INKT The first quarter conference call is summarized as follows:
MiNK Therapeutics (INKT) presented significant clinical data and mechanistic findings across diseases such as pulmonary fibrosis and refractory gastric cancer at multiple scientific conferences, highlighting promising results in survival and immune modulation.
The company initiated a randomized Phase 2 trial for Agent 797 in acute lung injury and ARDS, with a streamlined pathway for rapid development and potential FDA discussions for trial design.
Financially, MiNK Therapeutics (INKT) ended the quarter with
$9.5 million in cash, maintaining a disciplined capital expenditure with a runway for at least the next 12 months, while focusing on advancing clinical programs efficiently.
Looks good...especially the financial runway for the next year!!!
